Royalty Report: Drugs, Cancer, Drug Discovery – Collection: 306496

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Cancer
  • Drug Discovery
  • Therapeutic
  • Antibody
  • HIV / AIDs
  • Delivery
  • Diagnostic
  • Disease
  • Biotechnology
  • Ophthalmological
  • Molecular

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 306496

License Grant
The Licensee was granted an exclusive license to certain Intellectual Property.
License Property
Licensor is the exclusive licensing agent for a University and representing Mayo Clinic’s interests in certain patents and intellectual property rights.  The Intellectual Property encompasses the inhibition of tumor growth using compounds that inhibit QSOX1 enzymatic activity and, specifically, to anti-neoplastic compounds targeting QSOX1 (the parent molecule referred to as SBI-183).

The enzyme Quiescin Sulfhydryl Oxidase 1 (QSOX1) is a master regulator of extracellular matrix remodeling, and its overexpression by tumor cells.  Overexpression of QSOX1 has been unambiguously linked to promoting tumor invasion and metastasis.  It has been discovered that a small molecule SBI-183 inhibited the enzymatic activity of QSOX1 and as a result suppressed tumor cell invasion in vitro and metastasis of breast tumor cells in vivo.

This license is to technology relating to SBI-183, an anti-metastatic compound suppressing tumor cell growth and blocking metastasis.  Small molecule SBI-183 inhibited the enzymatic activity of QSOX1 and as a result suppressed tumor cell invasion in vitro and metastasis of breast tumor cells in vivo. Through its medicinal chemistry efforts the Licensee synthesized multiple structural analogs of SBI-183 and unveiled SPX-1009 lead compound that demonstrated ten-fold improvement in suppressing invasion and metastasis in several cancer models.

SBI-183 enhances the activity of cytotoxic drugs in vitro.

Field of Use
Licensee was formed to develop a unique biomarker for cancer (QSOX1) as well as cancer diagnostic and therapeutic products based on QSOX1.  Licensee is a research and development company that aims to improve global cancer care through the development of proprietary therapeutics for inhibiting cancer growth and metastasis.

IPSCIO Record ID: 356954

License Grant
For the Development and Commercialization License, Licensor grants an exclusive license sublicenseable, under the Licensor Technology to research, make, have made and use Compounds in the Territory pursuant to the Next Gen Research Plan; to make or have made Licensed Compounds in the Territory for use in the manufacture of Licensed Products to develop, make, have made, use, sell, offer for sale, and import Licensed Products in the Field in the Territory; and, an exclusive license, sublicenseable, under the Licensor know-how to research Subsequent Compounds in the Territory, to make or have made Subsequent Compounds in the Territory for research use or for use in the manufacture of Subsequent Products and to develop, make, have made, use, sell, offer for sale, and import, Subsequent Products in the Field in the Territory; and,
an exclusive license, sublicenseable, under the Licensor know-how, solely after the end of the Restriction Period, to research, develop, make, have made, use, sell, offer for sale, and import Compounds in the Field in the Territory.

For the Research License, Licensor grants a perpetual, irrevocable, non-exclusive, non-sublicensable except to Third Party contractors and service providers performing for the benefit of Licensee,  license under the Licensor Technology and Licensee Technology to make, import, and use but not to sell or offer for sale Compounds for internal research purposes only.

Licensor grants an option to obtain an exclusive, sublicense from Licensor to certain Patent Rights licensed to Licensor under the Georgia Regents Research Institute License Agreement or Lankcnau Institute for Medical Research License Agreements, to research, develop, make, have made, use, sell, offer for sale and import Compounds and Licensed Products in the Field in certain countries in the Territory.

License Property
Licensor controls certain patents and know-how relating to its proprietary program regarding inhibitors of the IDO Target and TDO Target, including patents and know-hem covering the lead compound NLG919 and other compounds that are inhibitors of one or both targets.  IDO Target means indoleamine 2,3-dioxygenase 1.  TDO Target means tryptophan 2,3-dioxygenase.

Licensed Compound means NLG919 or any Next Generation Compound.

NLG919 means Licensor’s proprietary small molecule IDO inhibitor known as of the Execution Date as NLG919, as further described in IND 119045 or any enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug thereof.

Compound means a compound with a molecular weight of two thousand (2,000) Daltons or less], that hinds to and inhibits the activity of one or both of the 100 Target and TDO Target. with an IC50 of 1 µMor less in the applicable Enzymatic Assay, and that is being researched, developed or commercialized to exert its influence through the inhibition of one or both of the IDO Target or TDO Target, including NLG919, but excluding Indoximod.

Enzymatic Assay means, with respect to the IDO Target, the assay described in IND 119045 Document PD0l-MRMP01 1-SP04-E248, and, with respect to the TDO Target. Enzymatic Assay shall also include an alternate means of detecting the products of the enzyme reactions or minor changes in the above enzyme assay protocols, as agreed upon by the JRC. Any IC50s of control compounds measured with an alternate assay format should fall within 3-fold of the assay method.

Indoximod means Licensor’s proprietary small molecule IDO pathway inhibitor known as of the Execution Date as indoximod, or 1-methyl-D-tryptophan, or any, enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug thereof.

Field of Use
The agreement also calls for the Parties to engage in a research collaboration for the discovery of next generation IDO/TDO compounds, which represent potential breakthrough approaches to cancer therapy.

IDO pathway inhibitors are another class of immune check point inhibitors akin to the recently developed antibodies targeting CTLA-4, PD-1, and PD-L1 that represent potential breakthrough approaches to cancer therapy. The IDO pathway regulates immune response by suppressing T-cell activation which enables local tumor immune escape. Recent studies have demonstrated that the IDO pathway is active in many cancers, both within tumor cells as a direct defense against T-cell attack, and also within antigen presenting cells in tumor draining lymph nodes whereby this pathway promotes peripheral tolerance to tumor associated antigens (TAAs). When hijacked by developing cancers in this manner, the IDO pathway may facilitate the survival, growth, invasion and metastasis of malignant cells whose expression of TAAs might otherwise be recognized and attacked by the immune system. NewLink has a number of active programs directed at synthesizing inhibitors to the IDO pathway and additionally has discovered novel tryptophan-2,3-dioxygenase (TDO) specific inhibitors that are potential anti-cancer compounds which could function individually or in combination with IDO inhibition.

Indication means any separately defined. well-categorized class of human disease, syndrome or medical condition for which a separate MAA may be filed with a Regulatory Authority. Each different tumor type or a different hematological malignancy as classified by cell lineage (e.g., acute lymphoblastic leukemia is a different Indication from chronic myclogenous leukemia) shall be a separate Indication; however each different line of therapy for a particular tumor type or hematological malignancy will not he considered a separate Indication.

IPSCIO Record ID: 227271

License Grant
The University grants to Licensee
– the exclusive worldwide license in the Field of Use to use the Patent to manufacture and sell the Product; and,
– the right to grant sublicenses to any Patent licensed exclusively hereunder, provided that any Sublicensee agrees to be bound by the terms and conditions of this Agreement applicable to Sublicensees.

The agreement is exclusive except for the non-exclusive license granted to the U.S. government

License Property
The patents are for Method and Composition for Angiogenesis Inhibition, Generation And Use Of Mab FM155 To Inhibit Angiogenesis and Tumor Growth, and, Generation And Use Of MABXL313 To Inhibit
Angiogenesis And Tumor Growth In Vivo.

2805 60/114,878 January 6, 1999 Method and Composition for Angiogenesis Inhibition

2806 60/114,877 January 6, 1999 Method and Composition for Angiogenesis Inhibition

2908 60/143,581 July 13, 1999 Generation And Use Of Mab FM155 To Inhibit Angiogenesis and Tumor Growth

2909 60/143,534 July 13, 1999 'Generation And Use Of MAB XL313 To Inhibit Angiogenesis And Tumor Growth In Vivo

Anti-Angiogenesis for the Treatment of Cancer

In a process known as angiogenesis, cancer cells stimulate the formation of new blood vessels in order to bring oxygen and nutrients to rapidly-growing tumor tissue. The onset of angiogenesis is caused mainly by tumor cell production of growth factors that activate the cells that line the blood vessels. These activated cells begin to divide and lead to the remodeling of the extracellular matrix, which is a dense protein network that provides support and growth signals for blood vessels and tumors.

Field of Use
Field of Use shall mean any field of use.

IPSCIO Record ID: 322463

License Grant
Licensor sold Leronlimab to Licensee where Licensee is responsible for all development, manufacturing and commercialization efforts.
License Property
Leronlimab (PRO 140) is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including certain liver diseases.

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control.  Blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer.

Field of Use
The field of use is for the treatment in HIV infection, tumor metastases, and other diseases including certain liver diseases.

HIV (human immunodeficiency virus) is a virus that attacks cells that help the body fight infection.
Metastasis means that cancer spreads to a different body part from where it started.
Liver cancer is the growth and spread of unhealthy cells in the liver.

Licensee is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.

IPSCIO Record ID: 203444

License Grant
The Canadian Licensor grants to the Israeli Licensee an exclusive, even as to Licensor, right and license throughout the Territory, with the right to grant sublicenses, under the Licensor Intellectual Property
– to Develop, have Developed, make, have made, and use the Licensed Compound and Licensed Product in the Field, and
– to sell, offer for sale, register, Commercialize and otherwise exploit the Licensed Product in the Field; provided that notwithstanding the exclusive rights granted to Licensee in the foregoing grant, Licensor shall retain the limited right to use the Licensor Intellectual Property to the extent necessary to perform its express obligations under this Agreement, including the Clinical Development Plan,  to conduct the Licensor Clinical Studies,  subject to the approval of the Joint Steering Committee, and as otherwise agreed to in writing by the Parties.

The exclusivity of the sublicense granted under such Licensor Intellectual Property is subject to the applicable non-exclusivity terms in the another Agreement.

Included with this agreement is also a non-exclusive, non-sublicensable, except to subcontractors as permitted under this Agreement, solely to permit such subcontractors to perform Licensors assigned responsibilities under the Clinical Development Plan, royalty-free, fully-paid right and license, by Licensee to Licensor under the Licensee Know-How and Licensee Patent Rights, solely to the extent necessary to conduct the activities assigned to Licensor by the Joint Steering Committee under the Clinical Development Plan.

License Property
The licensed property includes
TRPM-2 Antisense Therapy;
TRPM-2 Antisense Therapy and Combination composition;
TRPM-2 Antisense Therapy Using ai Oligonucleotide Having 2-0-(2- Methoxy)Ethyl Modifications Compound;
Chemo-and radiation-sensitization or cancer by antisense TRPM-2 oligodcoxynucleotides;
Treatment of Melanoma by Reduction in Clusterin Levels;
Clusterin antisense therapy for treatment of cancer;
Treatment of Cancer By Perturbation of Clusterin Levels;
Human Type 2 RNASE H;
Gapped Oligonucleotides, Directed to Gapmer and Hemimer Compounds with 2-O-ALKYL modifications;
2-O-Modified Nucleosides and Phosphoramidites; and others.

The collaboration agreement is for developing and commercializing OGX-011. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance. OGX-011 is expected to be used as adjunct therapy to enhance the effectiveness of chemotherapy and has shown promising results when added to currently available chemotherapies in several tumor types addressing a significant unmet medical need.

Field of Use
The Field means the prevention, diagnosis or treatment of any disease or medical condition in humans.  Specific fields addressed in the patents include prostate cancer cells, human renal cell cancer (RCC) cells and some breast cancer cells.

IPSCIO Record ID: 7111

License Grant
The Licensor, non-profit hospital, grants to Licensee the exclusive, worldwide License, with the right to grant subLicenses, to conduct research, develop Products, modify existing and/or future Products, and market such Products in the Field of Use using the Patent Rights and/or the Technical Information and to develop, use, make, have made, practice, import, carry out, manufacture, have manufactured, offer for sale, sell and/or have sold Products in the Field of Use in the territory using the Patent Rights and/or the Technical Information.
License Property
The Licensor owns and is entitled to grant License rights with respect to certain Patent Rights and Technical Information invented or developed in the course of the Licensor’s Molecular Oncology Research Program in the field of human therapeutic products, including new pharmaceutical products and/or non-prescriptive products based on, or utilizing the Patent Rights and/or Technical Information developed in the course of the Program.

Product or Products shall mean any human therapeutics, diagnostics (including algorithms or any components thereof), bioinformatics and any other human health care products and/or services in the Field of Use utilizing or derived in any manner whatsoever from any of the Patent Rights, Technical Information or Licensee Improvements, which Product(s), except for the license granted hereunder, would infringe a Valid Claim, the Patent Rights or those Future Patent Rights licensed to Licensee.

Licensee has developed a new anti-cancer agent as well as a new methodology specific for the treatment of invasive tumors such as glioblastoma multiforme, the most aggressive form of brain cancer, as well as both Her2-positive and Her2-negative breast cancers.

Licensee believes this approach is effective against brain and breast cancer in rodents, significantly extending their longevity and decrease the tumor size. Licensee proposes to expand this proprietary technology to other forms of cancer treatments together with common eye diseases such as age-related macular degeneration and diabetic retinopathy.

The technology is a family of related nano-biopolymers collectively referred to as Polycefin™ that are capable of acting as a drug delivery and targeting platform for cancer therapy and diagnostics. The new nanoscale drug, Polycefin, based on Licensee’s delivery system, was developed and patented by Licensee’s scientists. It is non-toxic, non-immunogenic, and biodegradable. It is based on a naturally derived polymer, i.e., polymalic acid. A significant feature of this novel agent is its ability to target multimeric tumor-associated proteins with one drug, a capability that other existing agents do not have. Licensee has proven that the significant anti-tumor and anti­angiogenic activity of this new drug is effective against both brain and breast cancers.

Polycefin are designed to target cancer cells and deliver a variety of bound therapeutics to them. In vivo pre-clinical studies have shown evidence that existing cancer drugs could have increased efficacy and reduced side effects when attached to the Polycefin  platform. Polycefin’s have the ability to harbor various drugs at the same time making it a master delivery vehicle that can be customized for a particular tumor and potentially for an individual patient.  Additionally, in vivo testing has shown efficacy against more than one type of cancer (breast and  brain) suggesting that Polycefin may have application to a wide range of cancer types, therapeutics and diagnostics.

Patent Rights
Title
Antisense Inhibition of Laminin-8 expression to Inhibit Human Gliomas
U.S. Patent & Trademark Office
Application No.
10/570,747
Filing Date
January 30, 2007
Patent No.
7,547,511
Issue Date
June 16, 2009

U.S. Patent & Trademark Office
Application No.
12/473,992
Filing Date
May 28, 2009

Japanese Patent Office
Application No.
2006-526391
Filing Date
September 13, 2004

Title
Polymalic Acid-Based Multifunctional Drug
Delivery System
U.S. Patent & Trademark Office
Application No.
10/580,999
Filing Date
March 12, 2007

European Patent Office
Application No.
04813049.6
Filing Date
December 3, 2004

Japanese Patent Office
Application No.
2006-542822
Filing Date
December 3, 2004

Title
Poly(Beta Malic Acid) with Pendant Leu-Leu-Leu
Tripeptide for effective Cytoplasmic Drug deliver

U.S. Patent & Trademark Office
Application No.
PCT/US2009/40252
Filing Date
April 10, 2009

Title
Drug delivery of Temozolomide for Systemic based treatment of Cancer
U.S. Patent & Trademark Office
Application No.
61/285,495
Filing Date
December 10, 2009

Field of Use
Field of Use shall mean human therapeutic products, including new pharmaceutical products and/or non-prescriptive products based on, or utilizing the Patent Rights and/or Technical Information developed in the course of the Program.

IPSCIO Record ID: 281390

License Grant
Licensee, a South Korean company, sublicensed from Licensor the patent and technology rights related to SP-2577 mesylate salt in South Korea, and for the right to develop, produce, manufacture, use and sell the drug in South Korea. Each party has agreed to report to the other party any intellectual or tangible property improvements or enhancements, along with a written description and sample, and have granted the other party a license to use such improvements or enhancements.
License Property
SP-2577 is one of the drug names for LSD1 inhibitors helps drive cancer progression through demethylation of histones and by acting as a scaffolding protein within various activator and repressor complexes.

SP-2577, is a small molecule that inhibits the epigenetic enzyme lysine specific demethylase 1 (“LSD1”). LSD1 is an enzyme that removes mono- and di-methyl marks on histones (core protein of chromatin) to alter gene expression. LSD1’s enzymatic activity can cause genes to turn on or off and thereby affect the cell’s gene expression and overall activity. In addition, LSD1 can act via its scaffolding properties, independently of its enzymatic function, to alter gene expression and modulate cell fate.  LSD1 is an enzyme that is, in part, responsible for epigenetic regulation of genes that support cancer growth.

Field of Use
SP-2577 is in Phase I/II clinical trial for the treatment of advanced solid tumors.

IPSCIO Record ID: 203348

License Grant
The Parties enter into an agreement for Licensor to design and synthesize glucokinase activators (GKAs) based on the lead molecules provided by Licensee and input obtained from the in vitro and in vivo testing of the molecules to be synthesized by Licensor as GKAs.

Licensee shall provide lead molecules that will be used by Licensor to design and synthesize molecules optimized for activation of the Target.

The Parties shall use commercially reasonable efforts to design and synthesize molecules that are optimized for activation of the Target Molecules based on the lead molecules provided by Licensee.

Licensor shall provide the structure of each such Molecule and any information about the Molecule that is available.

Licensor shall promptly assign to Licensee all such related intellectual property.

License Property
The Product means a pharmaceutical product that contains a Molecule,  that is conceived as a part of the Project,  considered by the Joint Committee for synthesis as a Molecule, and which either could have been reduced to practice by Licensor but for the Project ending or is reduced to practice by Licensee, the  Compound.
Field of Use
Licensor shall have the right to use the Molecules for screening purposes, except against the Target.  The target that is to be activated is glucokinase.

Glucokinase is an enzyme that facilitates phosphorylation of glucose to glucose-6-phosphate. Glucokinase occurs in cells in the liver and pancreas of humans and most other vertebrates.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.